Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and Regeneron ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...

Turns out it’s about the price of a gas station coffee. Regeneron Pharmaceuticals just scooped up 23andMe and its treasure trove of 15 million customer DNA profiles for a bargain basement $256 ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services. By Michael Levenson 23andMe, the genetic ...

Regeneron Pharmaceuticals will acquire ... Read next BI Tech Memo An icon in the shape of an angle pointing down.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

Leerink Partners downgraded while Truist defended Regeneron (NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against Amgen (NASDAQ:AMGN) biosimilar for its ...

TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on ...

Meacham argues Regeneron's Eylea franchise and melanoma pipeline optionality leave it well-positioned, raising his price target to $700 from $600 after a roughly 55% stock pullback since last year ...